Enison

There is no image.

Vindesine

Method of action: Antitumour

Treatment option: Malignant Melanoma, Carcinoma, Leukemia, Cancer, Surgery, Chronic Granulocytic Leukemia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enison

Quick Facts

Property	Description
Active ingredient	Vindesine sulfate
Form	Powder for solution for injection
Pharmacological class	Antineoplastic Agent, Vinca Alkaloid
Common Use	Targeting and inhibiting rapidly dividing malignant cells
Origin	Semisynthetic

What is Enison (Vindesine) and What Type of Medicine is It?

Enison is a trade name for a highly specialized prescription-only medication whose active substance is Vindesine, typically formulated as Vindesine sulfate. It is classified as an antineoplastic agent—a drug specifically designed to combat cancer—and belongs to the chemical group known as Vinca alkaloids. This classification confirms its fundamental therapeutic role in targeting and inhibiting the growth of malignant cells.

Vindesine is distinguished within its class because it is a semisynthetic derivative of the natural compound vinblastine, originating from the Catharanthus roseus plant (Madagascar periwinkle). It is designated as a potent cytotoxic drug used in structured chemotherapy protocols, reflecting its established clinical positioning as an inhibitor of cell proliferation.

Composition, Form, and Delivery Route

The active substance, Vindesine sulfate, is generally supplied as a powder for solution for injection in a vial, which is a key identity feature designed for maximum stability prior to use. It is reconstituted with an aqueous vehicle to create the final injectable solution. This preparation is strictly for intravenous (IV) administration. This route is essential, as the drug must be delivered directly and systemically into the bloodstream to ensure its uniform distribution and clinical efficacy against malignant tissues throughout the body.

Why is Vindesine Used? (General Purpose)

The general purpose of Vindesine is rooted in its function as an antimitotic agent, meaning it interferes with the cellular process of division. It works by acting as a microtubule-disrupting agent, which binds to tubulin and prevents the formation of the mitotic spindle. By causing the cell cycle to arrest in the metaphase, Vindesine effectively blocks the ability of rapidly proliferating cells to multiply. This interruption of proliferation is the core therapeutic action that makes the drug useful in controlling the growth of malignant cells.

What side effects are possible with Enison?

Enison: Possible Side Effects and Safety Information

This section outlines the documented adverse reactions and critical safety information for Enison, as summarized in regulatory documents, without offering medical advice.

Common and Clinically Significant Adverse Reactions

The adverse reactions associated with Enison primarily affect the Nervous System and the Gastrointestinal System. Data is frequently categorized by the CIOMS III/IV conventions, where an event occurring in 10% or more of patients is considered Very Common.

Very Common adverse reactions typically include headache and somnolence (drowsiness). The incidence and severity of certain central nervous system (CNS) effects, such as dizziness and somnolence, have been noted to exhibit a dose-dependent pattern.

Serious Safety Risks

Certain reactions, although Rare or Very Rare, are classified as serious and clinically significant due to their potential severity. These include:

Agranulocytosis: A rare, potentially life-threatening decrease in a type of white blood cell (neutrophils) that requires immediate discontinuation and mandatory routine complete blood count monitoring during the initial months of therapy.
Seizures: Documented as an Uncommon but serious neurological event.
Severe Cutaneous Adverse Reactions (SCARs): Very rare, post-marketing reports include severe skin reactions like Stevens-Johnson Syndrome. Immediate discontinuation upon the first sign of an unexplained rash is required.

Restrictions and Special Safety Considerations

Enison is Contraindicated in individuals with a known hypersensitivity to the active substance or any of its excipients. Specific patient populations require particular caution:

Pediatric Use: Use in patients under 12 years of age is not recommended due to an observed increased risk of specific neurological adverse events in this group.
Hepatic Impairment: Patients with liver impairment may require dose adjustment and heightened safety monitoring due to a risk of elevated liver enzymes, particularly with prolonged treatment.

Safety Monitoring

Official labeling mandates routine monitoring, such as the complete blood count (CBC), to detect serious hematological effects early. Discontinuation is explicitly required if signs of hepatic dysfunction or certain adverse reactions occur.

Overdose and Emergency Response

The official regulatory documentation states that an overdose of Enison (Vindesine sulfate) may result in a very serious or fatal outcome. Overdosage is characterized by severe and prolonged dose-limiting toxicities, primarily granulocytopenia (low white blood cell count) and increased neurotoxicity. Documented clinical signs may include acute abdominal pain, which can precede paralytic ileus, and thrombocytopenia (low platelet count).

Immediate medical attention must be sought if an overdose is suspected. The most severe, life-threatening scenario is the accidental intrathecal administration (into the spine), which is documented to cause ascending paralysis leading to death. This error requires immediate neurosurgical intervention as a mandated emergency action.

Management is strictly symptomatic and supportive, as no specific antidote is known. Patients with severe granulocytopenia must be watched carefully for evidence of infection until blood counts stabilize. Supportive measures such as CSF irrigation may be employed for intrathecal errors. Patients with existing hepatic or biliary function impairment are noted to have an increased toxicity risk, which may mimic an overdose scenario.

Therapeutic Uses of Enison

What Enison Treats: Main Uses and Benefits

The primary therapeutic domain of Enison is relevant across conditions presenting with systemic or localized discomfort. Its active ingredient is commonly used to help with symptoms that create noticeable physiological strain.

Enison is applied across domains where additional symptomatic support is needed. Applications include the categories of Rheumatic Disorders, Allergic States, Respiratory Diseases, and certain Dermatologic and Gastrointestinal Diseases.

The medication assists with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened physiological activity or flare-ups. It is often used during phases when symptoms become more noticeable, in contexts involving heightened systemic burden.

“Enison is relevant for easing symptom clusters that may become intense or disruptive, helping to support the patient during difficult episodes.”

Quick Fact: Relevant for Symptom Clusters

Regulatory References

DailyMed official labeling for Prednisone

Eligibility and Restrictions for Use

Who Can and Cannot Use Enison (Vindesine Sulfate)

Official regulatory information strictly defines the patient populations eligible to use Enison (Vindesine sulfate), a potent cytotoxic agent. Eligibility is established for adult and pediatric patients receiving antineoplastic therapy. However, use is severely restricted or absolutely prohibited in certain groups.

Contraindicated Populations (Must Not Use)

Contraindication	Status
Hypersensitivity to vindesine or Vinca alkaloids	Absolute Contraindication
Pregnancy or Lactation (Breastfeeding)	Absolute Contraindication
Charcot-Marie-Tooth syndrome (demyelinating form)	Absolute Contraindication
Uncontrolled bacterial infection	Contraindicated

Condition-Based Restrictions (Conditional Use)

Patients with hepatic impairment (liver trouble or jaundice) require mandatory dose modification due to the drug’s primary route of elimination. Individuals with pre-existing neurological disease or neuropathy are at increased risk of neurotoxicity, and treatment must proceed only under close specialist supervision. Furthermore, the medicine is restricted to intravenous (IV) administration only, as administration by any other route, such as intrathecal injection, is strictly contraindicated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Enison (Vindesine, a Vinca alkaloid) is structured around metabolic clearance and potential for additive toxic effects, as detailed in regulatory labeling.

Interaction Scope and Constraints

Category	Official Regulatory Statement
High-Risk Combinations	Co-administration with Mitomycin-C is associated with severe bronchospasm and fatal acute respiratory distress.
Metabolic Basis	The clearance of the drug is mediated by hepatic CYP 3A isoenzymes.
Exposure Modifiers	CYP 3A Inhibitors (e.g., Itraconazole, Erythromycin) decrease clearance, leading to increased plasma exposure and amplified neuromuscular side effects.
Pharmacodynamic Effects	Additive neurotoxicity is a risk with other neurotoxic drugs. Co-use with Phenytoin is reported to reduce Phenytoin blood levels and increase seizure activity.
Timing-Based Rules	The efficacy of Bleomycin is documented to be enhanced if the Vinca alkaloid is administered six to eight hours prior to the Bleomycin dose.
Population Note	Hepatic dysfunction increases the risk of toxicity from interactions due to impaired metabolism via the liver-dependent CYP 3A pathway.

Official Interaction Summary

The regulatory profile explicitly warns that strong inhibitors of the CYP 3A subfamily can decrease the metabolism of the Vinca alkaloid, resulting in higher drug concentrations and a higher likelihood of toxicity. Furthermore, combinations that cause combined systemic risk are restricted: this includes the high-risk combination with Mitomycin-C and caution with other neurotoxic agents. The role of the P-glycoprotein (P-gp) transporter is also noted as relevant to drug exposure for this class of medicine.

Mechanism of Action

The final output describes the drug's mechanism of action, detailing its biological targets, pathways, and physiological consequences.

Selective Enzyme Inhibition

Enison functions as a selective competitive inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This molecular mechanism prevents the COX-2 enzyme from converting its natural substrate into pro-inflammatory chemical messengers. This initial step is central to the drug's pharmacodynamic action, modifying the early molecular steps that shape subsequent systemic physiological adjustments.

Modulation of Prostaglandin Signaling Cascades

The enzyme inhibition leads to a rapid downregulation of the Prostaglandin Biosynthesis Pathway, which in turn dampens the Systemic Inflammatory Mediator Cascade. This change in chemical signaling modifies the capacity of the system to generate and sustain an amplified mediator response, contributing to pathway equilibrium within the targeted systems.

Dual Central and Peripheral Action

The mechanism engages COX-2 pathways in both peripheral tissues and central nervous system structures. This dual action modulates localized COX-2 activity and influences the degree of nerve sensitization and signaling within sensory pathways.

Dosage and Administration Information

Enison (Vindesine sulfate) is a specialized medication that is strictly formulated as a powder for solution for injection and is approved exclusively for intravenous (IV) administration. This antineoplastic agent must be introduced directly into a vein or into the tubing of a running IV infusion; the use of any other route is strictly prohibited.

The dosage regimen is determined by the patient’s body surface area (BSA), measured in square meters. The standard adult starting dose is 3 mg/m^2 weekly. Administration is constrained to a weekly interval and must not occur more frequently than once every seven days. This schedule defines the core use pattern over time.

Prior to administration, the powder requires careful reconstitution with an appropriate sterile solution, such as 0.9% sodium chloride. Due to the potent nature of the medicine, its administration must be conducted under the supervision of personnel experienced in chemotherapy protocols. Clinical protocols may include population-specific adjustments: for example, the dose may require reduction in the presence of significantly impaired hepatic or biliary function. Furthermore, the weekly dosing is conditional, as the next scheduled dose must be withheld until the patient has recovered from any effects resulting from the prior administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Enison (Vindesine)

The available research evidence for Enison (Vindesine) is based primarily on its classification as an antineoplastic agent that was studied in structured chemotherapy regimens. The studies were designed to explore how outcomes evolved, predominantly when used alongside other medications as part of a combination protocol across various cancer types.

Evidence Base for Acute Leukemia

Research has explored Vindesine's role in the study of acute leukemia, including Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). Studies often involve Randomized Controlled Trials (RCTs) where the agent is a specific component within a multi-drug regimen, or Phase I/II trials which explored its use in patients with disease that was relapsed or refractory. The studies used outcomes related to disease status, such as the rate at which cohorts achieved Complete Remission or a Partial Response, and also tracked longer-term metrics like Overall Survival and metrics for Disease-Free Survival.

Research reports noted that properties of the agent that were relevant to safety often placed structural constraints on the dose used in trials, which may affect how results are interpreted. The evidence is largely focused on combination protocols, meaning research exploring the medicine’s role as a single agent in leukemia is limited.

Research Landscape for Lymphomas

Vindesine was studied for both Hodgkin's Disease and Non-Hodgkin's Lymphomas. Trials primarily involved RCTs comparing different multi-agent chemotherapy regimens. The research examined outcomes reflecting disease response and long-term data points, including Progression-Free Survival and Overall Survival. The studies monitored patterns over defined time intervals, and evidence contributes to understanding symptom patterns.

The studies used trial designs that are often categorized as carrying higher consistency, but this applies to the protocol as a whole. This research is heavily weighted toward combination protocols, making the isolation of Vindesine's role from the effects of the entire regimen complex. Subgroup findings across varying severities of disease are often uncertain, and the bulk of the research focuses on the core disease indications.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Enison (FAQ)

Q: What happens if I take Enison with alcohol?

Official product information notes that the drug belongs to a class associated with neurotoxicity, which describes effects on the nervous system. Regulatory documents suggest this potential for nervous system effects is the reason alcohol use may be viewed with caution. This is due to the potential for an additive increase in these effects.

Q: Are there any foods or supplements that are officially listed as interacting with Enison?

The active substance in Enison is cleared (metabolized) by a specific enzyme system in the liver. Some official regulatory documents for vinca alkaloids note a concern regarding grapefruit juice. This is because grapefruit juice may inhibit the enzyme, which could potentially lead to higher concentrations of the drug in the bloodstream and increase the risk of toxicity.

Q: If I stop taking Enison, how long will it take for the medicine to leave my system?

Pharmacokinetic data from official sources indicates that the active ingredient, Vindesine, is eliminated from the body in phases. The final phase of elimination has an approximate half-life of 24 hours. The drug is mainly broken down (metabolized) by the liver.

Q: Is Enison known to be safe for older adults (seniors)?

Official regulatory guidance suggests that the standard adult dosage schedule is generally applied to older adults. Health authorities note that doses may need modification if the patient has other health concerns, particularly impaired liver function or significant weight loss (cachexia). The official information notes that careful monitoring is relevant for this patient group.

Q: What types of heart conditions are listed as reasons not to use Enison?

Heart conditions are not classified as absolute contraindications that strictly prohibit the use of Enison. However, the medicine belongs to a class of drugs that requires caution in individuals with pre-existing ischemic cardiac disease. Official information notes that there is a rare, documented risk of cardiovascular damage or vasospasm (narrowing of blood vessels) associated with this class.

Q: Can I take Enison if I already take a daily vitamin or herbal supplement?

Official product information notes the importance of informing the healthcare provider about all substances being taken. This includes all prescribed or non-prescribed medicines, as well as vitamins, minerals, herbal products, and any other supplements. This practice supports the assessment of potential drug interactions.

Q: Does Enison carry a Black Box Warning in the U.S. and what does that mean?

Yes, the U.S. FDA label for this class of medicine includes a Boxed Warning, which is the agency’s strictest warning level. This warning explicitly states that the drug is FOR INTRAVENOUS USE ONLY (delivered into a vein). The warning emphasizes that administration by any other route could be fatal.

Q: Is Enison intended for short-term or long-term management?

Enison is administered as part of structured chemotherapy protocols, typically on a weekly interval. Official regulatory documents indicate that continuous administration using small daily doses for prolonged periods is not part of the established regimen. Its use is determined by the specific treatment plan defined by the prescribing specialist.

Q: Can Enison cause changes in appetite or weight?

Yes, official regulatory-cited data for the class of medicine Enison belongs to lists changes in appetite and weight as possible common side effects. Specifically, reports have documented both a loss of appetite and unintended weight loss in some patients receiving treatment.

Q: Is there a generic version of Enison available?

The active ingredient in Enison is Vindesine sulfate. This active ingredient is commercially available as a generic drug product. However, the specific availability of the generic version, its brand name, and its formulation may differ depending on the specific country or region.

Q: Do studies suggest that lifestyle changes are needed while taking Enison?

Regulatory guidance notes that because the drug may affect the nervous system, attention to preventing constipation is relevant. This is a common precaution associated with this class of medication. Any further lifestyle or diet modifications would be addressed by the patient's specific oncology team.

How should Enison be stored and disposed of?

How to Store and Dispose of Enison

The storage and disposal of Enison (Vindesine sulfate), a cytotoxic agent, must strictly adhere to regulatory requirements to ensure product stability and prevent hazardous exposure.

Official Storage Conditions

The unopened vial must be stored in a refrigerator at a temperature between 2 C and 8 C. To protect the medicine from light, it must be kept in its original outer carton. For safety, the product must be stored out of the sight and reach of children and handled only by trained personnel using personal protective equipment.

Required Disposal

Unused or expired Enison must not be disposed of in household waste or wastewater. As a hazardous substance, it requires disposal according to specific national and local regulations for cytotoxic waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Spain

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z